163 related articles for article (PubMed ID: 11400121)
21. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401.
; Tanner M; Isola J; Wiklund T; Erikstein B; Kellokumpu-Lehtinen P; Malmström P; Wilking N; Nilsson J; Bergh J
J Clin Oncol; 2006 Jun; 24(16):2428-36. PubMed ID: 16682728
[TBL] [Abstract][Full Text] [Related]
22. Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers.
Sjögren S; Inganäs M; Lindgren A; Holmberg L; Bergh J
J Clin Oncol; 1998 Feb; 16(2):462-9. PubMed ID: 9469329
[TBL] [Abstract][Full Text] [Related]
23. Amplification of HER-2(erbB-2/neu) oncogene as the most significant prognostic factor in a group of Russian breast cancer patients.
Imyanitov EN; Chernitsa OI; Serova OM; Nikoforova IF; Pluzhnikova GF; Knyazev PG
Neoplasma; 1993; 40(1):35-9. PubMed ID: 7688867
[TBL] [Abstract][Full Text] [Related]
24. Prognostic association of c-erbB-2 oncogene amplification and protein overexpression in human breast cancer using archival tissues. A comparative study.
Bandyopadhyay D; Redkar A; Bharde S; Dani H; Sampat M; Mittra I
Acta Oncol; 1994; 33(5):493-8. PubMed ID: 7917361
[TBL] [Abstract][Full Text] [Related]
25. Predictive value of c-erbB-2 and cathepsin-D for Greek breast cancer patients using univariate and multivariate analysis.
Scorilas A; Yotis J; Pateras C; Trangas T; Talieri M
Clin Cancer Res; 1999 Apr; 5(4):815-21. PubMed ID: 10213217
[TBL] [Abstract][Full Text] [Related]
26. c-erbB-2 amplification in node-negative human breast cancer.
Ro JS; el-Naggar A; Ro JY; Blick M; Frye D; Fraschini G; Fritsche H; Hortobagyi G
Cancer Res; 1989 Dec; 49(24 Pt 1):6941-4. PubMed ID: 2573424
[TBL] [Abstract][Full Text] [Related]
27. Int-2/FGF3 amplification is a better independent predictor of relapse than c-myc and c-erbB-2/neu amplifications in primary human breast cancer.
Champème MH; Bièche I; Hacène K; Lidereau R
Mod Pathol; 1994 Dec; 7(9):900-5. PubMed ID: 7892157
[TBL] [Abstract][Full Text] [Related]
28. Prognostic value of the quantitative measurement of the oncoprotein p185(Her-2/neu) in a group of patients with breast cancer and positive node involvement.
Bohn U; Aguiar J; Bilbao C; Murias A; Vega V; Chirino R; Díaz-Chico N; Díaz-Chico JC
Int J Cancer; 2002 Oct; 101(6):539-44. PubMed ID: 12237894
[TBL] [Abstract][Full Text] [Related]
29. Immunohistochemical study of c-erbB-2 expression in primary breast cancer.
Chearskul S; Onreabroi S; Churintrapun M; Semprasert N; Bhothisuwan K
Asian Pac J Allergy Immunol; 2001 Sep; 19(3):197-205. PubMed ID: 11826915
[TBL] [Abstract][Full Text] [Related]
30. Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer.
Konecny GE; Thomssen C; Lück HJ; Untch M; Wang HJ; Kuhn W; Eidtmann H; du Bois A; Olbricht S; Steinfeld D; Möbus V; von Minckwitz G; Dandekar S; Ramos L; Pauletti G; Pegram MD; Jänicke F; Slamon DJ
J Natl Cancer Inst; 2004 Aug; 96(15):1141-51. PubMed ID: 15292386
[TBL] [Abstract][Full Text] [Related]
31. Prognostic significance of p34cdc2 cyclin-dependent kinase and MIB1 overexpression, and HER-2/neu gene amplification detected by fluorescence in situ hybridization in breast cancer.
Depowski PL; Brien TP; Sheehan CE; Stylos S; Johnson RL; Ross JS
Am J Clin Pathol; 1999 Oct; 112(4):459-69. PubMed ID: 10510669
[TBL] [Abstract][Full Text] [Related]
32. c-erbB-2 and ras expression levels in breast cancer are correlated and show a co-operative association with unfavorable clinical outcome.
Dati C; Muraca R; Tazartes O; Antoniotti S; Perroteau I; Giai M; Cortese P; Sismondi P; Saglio G; De Bortoli M
Int J Cancer; 1991 Apr; 47(6):833-8. PubMed ID: 1672666
[TBL] [Abstract][Full Text] [Related]
33. c-erbB-2 positivity is a factor for poor prognosis in breast cancer and poor response to hormonal or chemotherapy treatment in advanced disease.
Jukkola A; Bloigu R; Soini Y; Savolainen ER; Holli K; Blanco G
Eur J Cancer; 2001 Feb; 37(3):347-54. PubMed ID: 11239756
[TBL] [Abstract][Full Text] [Related]
34. Concordance in judgments among c-erbB-2 (HER2/neu) overexpression detected by two immunohistochemical tests and gene amplification detected by Southern blot hybridization in breast carcinoma.
Tsuda H; Tani Y; Hasegawa T; Fukutomi T
Pathol Int; 2001 Jan; 51(1):26-32. PubMed ID: 11148460
[TBL] [Abstract][Full Text] [Related]
35. c-erbB-2 status is an independent predictor of survival after first recurrence.
Horiguchi J; Iino Y; Takei H; Maemura M; Takeyoshi I; Yokoe T; Ohwada S; Oyama T; Nakajima T; Morishita Y
Int J Oncol; 1998 Jan; 12(1):123-8. PubMed ID: 9454895
[TBL] [Abstract][Full Text] [Related]
36. Expression of S100A4 and Met: potential predictors for metastasis and survival in early-stage breast cancer.
Lee WY; Su WC; Lin PW; Guo HR; Chang TW; Chen HH
Oncology; 2004; 66(6):429-38. PubMed ID: 15452371
[TBL] [Abstract][Full Text] [Related]
37. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
38. [Amplification of c-myc and c-erbbeta-2(HER-2/neu) in breast cancer without axillary lymph node metastasis: correlation with other prognostic parameters].
Lizard-Nacol S; Arnould L; Riedinger JM; Arnal M; Collin F; Guerrin J
Bull Cancer; 1994 Sep; 81(9):780-4. PubMed ID: 7703567
[TBL] [Abstract][Full Text] [Related]
39. Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu): a study of incidence and correlation with outcome in breast cancer.
Thor AD; Liu S; Edgerton S; Moore D; Kasowitz KM; Benz CC; Stern DF; DiGiovanna MP
J Clin Oncol; 2000 Sep; 18(18):3230-9. PubMed ID: 10986055
[TBL] [Abstract][Full Text] [Related]
40. A prospective study of the significance of gene and chromosome alterations as prognostic indicators of breast cancer patients with lymph node metastases.
Tsuda H; Sakamaki C; Tsugane S; Fukutomi T; Hirohashi S
Breast Cancer Res Treat; 1998 Mar; 48(1):21-32. PubMed ID: 9541186
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
